Recommendations for Prevention and Control of Influenza in Children, 2023–2024

Authoring Organization

Publication Month/Year

August 29, 2023

Supplemental Implementation Tools

Document Type


Country of Publication


Document Objectives

This statement updates the recommendations of the American Academy of Pediatrics for the routine use of influenza vaccine and antiviral medications in the prevention and treatment of influenza in children during the 2023–2024 influenza season. The American Academy of Pediatrics recommends annual influenza vaccination of all children without medical contraindications starting at 6 months of age. Children are at risk for hospitalization and death from influenza. Influenza vaccination is an important strategy for protecting children and the broader community, as well as reducing the overall burden of respiratory illnesses when other viruses are cocirculating. Any licensed influenza vaccine appropriate for age and health status can be administered, ideally as soon as possible in the season, without preference for one product or formulation over another.

Target Patient Population

Children and adolescents who have influenza and/or who may be eligible to receive influenza vaccinations

Target Provider Population

Pediatricians and other clinicians caring for children

Inclusion Criteria

Male, Female, Adolescent, Child, Infant

Health Care Settings

Ambulatory, Childcare center, School

Intended Users

Nurse, nurse practitioner, physician, physician assistant


Treatment, Prevention

Diseases/Conditions (MeSH)

D007252 - Influenza Vaccines, D007251 - Influenza, Human


influenza, influenza vaccines, pediatric influenza, pediatric vaccines

Source Citation

COMMITTEE ON INFECTIOUS DISEASES; Recommendations for Prevention and Control of Influenza in Children, 2023–2024. Pediatrics 2023; e2023063772. 10.1542/peds.2023-063772

Supplemental Methodology Resources

Technical Review